Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yu, Yongmei ^a   Zhang, Xian H ^a   Ebersole, Blake ^b   Ribnicky, David ^c   Wang, Zhong Q ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b Verdure Sciences   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PLANT EXTRACT; SIRT1 PROTEIN, MOUSE; SIRTUIN 1;

ANALYSIS; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; FATTY LIVER; FRUIT; GLUCOSE BLOOD LEVEL; LIPID DIET; LIVER; MALE; METABOLISM; MOMORDICA CHARANTIA; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; DOWN-REGULATION; FATTY LIVER; FIBROBLAST GROWTH FACTORS; FRUIT; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; MOMORDICA CHARANTIA; PLANT EXTRACTS; SIGNAL TRANSDUCTION; SIRTUIN 1; UP-REGULATION;

EID: 84889675289     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03142     Document Type: Article

References (47)

1. Ching, R. H. et al. Supplementation of bitter melon to rats fed a high-fructose diet during gestation and lactation ameliorates fructose-induced dyslipidemia and hepatic oxidative stress in male offspring. J. Nutr. 141, 1664-1672 (2011)
2. Misra, A. & Khurana, L. Obesity and the metabolic syndrome in developing countries. J. Clin. Endocrinol. Metab. 93, S9-30 (2008)
3. Lenfant, C. et al. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002)
4. Neuschwander-Tetri, B. A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 52, 774-788 (2010)
5. Bottcher, R. T. & Niehrs, C. Fibroblast growth factor signaling during early vertebrate development. Endocr. Rev. 26, 63-77 (2005) (Pubitemid 40209387)
6. Powers, C. J., McLeskey, S. W. & Wellstein, A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 7, 165-197 (2000)
7. Kliewer, S. A. & Mangelsdorf, D. J. Fibroblast growth factor 21: From pharmacology to physiology. Am. J. Clin. Nutr. 91, 254S-257S (2010)
8. Angulo, P. Obesity and nonalcoholic fatty liver disease. Nutr. Rev. 65, S57-63 (2007)
9. Cowie, C. C. et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care. 29, 1263-1268 (2006) (Pubitemid 44125920)
10. Kharitonenkov, A. & Larsen, P. FGF21 reloaded: Challenges of a rapidly growing field. Trends Endocrinol Metab. 22, 81-86 (2011)
11. Ge, X. et al. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J. Biol. Chem. 286, 34533-34541 (2011)
12. Chau, M. D. et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl. Acad. Sci. U S A. 107, 12553-12558 (2010)
13. Chen, W. W. et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116, 65-68 (2008)
14. Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259 (2009)
15. Li, H. et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 53, 934-940 (2010)
16. Morris-Stiff, G. & Feldstein, A. E. Fibroblast growth factor 21 as a biomarker for NAFLD: Integrating pathobiology into clinical practice. J. Hepatol. 53, 795-796 (2010)
17. Chavez, A. O. et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32, 1542-1546 (2009)
18. Chen, C. et al. High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes: A 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34, 2113-2115 (2011)
19. Leung, L. et al. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): A mini review. Br. J. Nutr. 102, 1703-1708 (2009)
20. Nerurkar, P. V. et al.Momordica charantia (bitter melon) attenuates high-fat dietassociated oxidative stress and neuroinflammation. J. Neuroinflammation 8, 64 (2011)
21. Nerurkar, P. V. et al. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br. J. Nutr. 100, 751-759 (2008)
22. Sridhar, M. G., Vinayagamoorthi, R., Arul Suyambunathan, V., Bobby, Z. & Selvaraj, N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br. J. Nutr. 99, 806-812 (2008) (Pubitemid 351351634)
23. Tan, M. J. et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol. 15, 263-273 (2008)
24. Wang, Z. Q. et al. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. J. Nutr. Biochem. 22, 1064-1073 (2011)
25. Snee, L. S. et al. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): A vegetable commonly used for diabetes management. Nutr. J. 10, 78 (2011)
26. Fritsche, L., Weigert, C., Haring, H. U. & Lehmann, R. How insulin receptor substrate proteins regulate the metabolic capacity of the liver-implications for health and disease. Curr. Med. Chem. 15, 1316-1329 (2008) (Pubitemid 351997801)
27. Popovich, D. G., Lee, Y., Li, L. & Zhang, W. Momordica charantia seed extract reduces pre-adipocyte viability, affects lactate dehydrogenase release, and lipid accumulation in 3T3-L1 cells. J. Med. Food 14, 201-208 (2011)
28. Lo, H. Y., Ho, T. Y., Lin, C., Li, C. C. & Hsiang, C. Y. Momordica charantia and Its Novel Polypeptide Regulate Glucose Homeostasis in Mice via Binding to Insulin Receptor. J. Agric. Food Chem. (2013). Epub ahead of print
29. Sarruf, D. A. et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817-1824 (2010)
30. Mraz, M. et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. (Oxf). 71, 369-375 (2009)
31. Dushay, J. et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139, 456-463 (2010)
32. Fisher, F. M. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789 (2010)
33. Hojman, P. et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes. 58, 2797-2801 (2009)
34. Mai, K. et al. Free fatty acids link metabolism and regulation of the insulinsensitizing fibroblast growth factor-21. Diabetes 58, 1532-1538 (2009)
35. Kurosu, H. et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695 (2007) (Pubitemid 47501965)
36. Kharitonenkov, A. et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215, 1-7 (2008) (Pubitemid 351363185)
37. Lundasen, T. et al. PPARalpha is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 360, 437-440 (2007) (Pubitemid 47039157)
38. Mai, K. Bobbert et al. Physiologicalmodulation of circulating FGF21: relevance of free fatty acids and insulin. Am. J. Physiol. Endocrinol. Metab. 299, E126-130 (2010)
39. Huang, X., Yang, C., Luo, Y., Jin, C.,Wang, F.&McKeehan,W. L. FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet-Induced Fatty Liver. Diabetes 56, 2501-2510 (2007) (Pubitemid 47523257)
40. Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W. L. & Luo, Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7, e33870 (2012)
41. Li, H. et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J. Clin. Endocrinol. Metab. 94, 2151-2156 (2009)
42. Matthews, D. R. et al.Homeostasis model assessment: Insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28, 412-419 (1985) (Pubitemid 15018832)
43. Wang, Z. Q. et al. Effects of dietary fibers on weight gain, carbohydrate metabolism, and gastric ghrelin gene expression in mice fed a high-fat diet. Metabolism 56, 1635-1642 (2007) (Pubitemid 350060930)
44. Roukos, V. et al. Dynamic recruitment of licensing factor Cdt1 to sites of DNA damage. J. Cell. Sci. 124, 422-434 (2011)
45. Ney, D. M. et al. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria. J. Nutr. 138, 316-322 (2008) (Pubitemid 351213646)
46. Jensen, T. et al. Comparison of a homogeneous assay with a precipitationmethod for the measurement of HDL cholesterol in diabetic patients. Diabetes Care 25, 1914-1918 (2002) (Pubitemid 41071044)
47. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509 (1957)